Cargando…
Clinical Therapeutics in Pregnancy
Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139199/ https://www.ncbi.nlm.nih.gov/pubmed/21785566 http://dx.doi.org/10.1155/2011/783528 |
_version_ | 1782208435566149632 |
---|---|
author | Feghali, Maisa N. Mattison, Donald R. |
author_facet | Feghali, Maisa N. Mattison, Donald R. |
author_sort | Feghali, Maisa N. |
collection | PubMed |
description | Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy. |
format | Online Article Text |
id | pubmed-3139199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31391992011-07-22 Clinical Therapeutics in Pregnancy Feghali, Maisa N. Mattison, Donald R. J Biomed Biotechnol Review Article Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy. Hindawi Publishing Corporation 2011 2011-07-06 /pmc/articles/PMC3139199/ /pubmed/21785566 http://dx.doi.org/10.1155/2011/783528 Text en Copyright © 2011 M. N. Feghali and D. R. Mattison. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Feghali, Maisa N. Mattison, Donald R. Clinical Therapeutics in Pregnancy |
title | Clinical Therapeutics in Pregnancy |
title_full | Clinical Therapeutics in Pregnancy |
title_fullStr | Clinical Therapeutics in Pregnancy |
title_full_unstemmed | Clinical Therapeutics in Pregnancy |
title_short | Clinical Therapeutics in Pregnancy |
title_sort | clinical therapeutics in pregnancy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139199/ https://www.ncbi.nlm.nih.gov/pubmed/21785566 http://dx.doi.org/10.1155/2011/783528 |
work_keys_str_mv | AT feghalimaisan clinicaltherapeuticsinpregnancy AT mattisondonaldr clinicaltherapeuticsinpregnancy |